Type 2 Diabetes Mellitus Management in Canada: Is It Improving?

Canadian Journal of Diabetes

Volumn 37, Issue 2, 2013, Pages 82-89

  Leiter, Lawrence A ^a,b,c   Berard, Lori ^d   Bowering, C Keith ^e   Cheng, Alice Y ^a,b   Dawson, Keith G ^f   Ekoé, Jean Marie ^g   Fournier, Carl ^h   Goldin, Lianne ⁱ   Harris, Stewart B ^j   Lin, Peter ⁱ   Ransom, Thomas ^k   Tan, Mary ⁱ   Teoh, Hwee ^a   Tsuyuki, Ross T ^l   Whitham, Dana ^m   Woo, Vincent ⁿ   Yale, Jean François ^o   Langer, Anatoly ^a,b,i  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ CANADIAN HEART RESEARCH CENTRE   (Canada)

^j WESTERN UNIVERSITY   (Canada)

^k DALHOUSIE UNIVERSITY   (Canada)

^l UNIVERSITY OF ALBERTA   (Canada)

^m ST MICHAEL'S HOSPITAL   (Canada)

ⁿ UNIVERSITY OF MANITOBA   (Canada)

^o MCGILL UNIVERSITY   (Canada)

more..

Author keywords

Blood pressure; Care gap; Glycemic control; Guidelines; Lipids; Management; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATTITUDE TO HEALTH; BLOOD PRESSURE REGULATION; CANADA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COUNSELING; EXERCISE; FEMALE; GENERAL PRACTITIONER; GLYCEMIC CONTROL; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PATIENT ATTITUDE; AGED; ANALYSIS; BLOOD; BLOOD PRESSURE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSICIAN; PRACTICE GUIDELINE;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CANADA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84876014866     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.02.055     Document Type: Article

References (28)

1. Handelsman Y., Mechanick J.I., Blonde L., et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011, 17:287-302.
2. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in canada. Can J Diabetes 2008, 32:S1-S201.
4. Published by National Institute for Health and Clinical Excellence, Manchester, United Kingdom. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. 2012.
5. International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2012. http://www.idf.org/sites/default/files/IDF%20Guideline%20for%20Type%202%20Diabetes.pdf.
6. Holman R.R., Paul S.K., Bethel M.A., et al. Ten-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
7. Gaede P., Lund-Andersen H., Parving H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
8. Braga M.F., Casanova A., Teoh H., et al. Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. Int J Clin Pract 2012, 66:457-464.
9. Brown L.C., Johnson J.A., Majumdar S.R., et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004, 171:1189-1192.
10. Harris S.B., Ekoe J.M., Zdanowicz Y., et al. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada Evaluation Study). Diabetes Res Clin Pract 2005, 70:90-97.
11. Saydah S.H., Fradkin J., Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335-342.
12. Cheung B.M., Ong K.L., Cherny S.S., et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009, 122:443-453.
13. Bi Y., Zhu D., Cheng J., et al. The status of glycemic control: a cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu Province of China. Clin Ther 2010, 32:973-983.
14. Fox K.M., Gerber R.A., Bolinder B., et al. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the united kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006, 28:388-395.
15. Al Hamarneh Y.N., Rosenthal M., Tsuyuki R.T. Glycemic control in community-dwelling patients with type 2 diabetes. Can Pharm J 2012, 145:68-70.
16. World Health Organization Expert Consultation Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363:157-163.
17. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009, 25:567-579.
18. Canadian Hypertension Education Program. The 2012 CHEP recommendations for the management of hypertension. 2012. http://www.hypertension.ca/chep-recommendations.
19. Goodman S.G., Langer A., Bastien N.R., et al. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the Dyslipidemia International Study (DYSIS). Can J Cardiol 2010, 26:e330-e335.
20. Bourgault C., Davignon J., Fodor G., et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study-Observational (CALIPSO). Can J Cardiol 2005, 21:1187-1193.
21. McPherson R., Frohlich J., Fodor G., et al. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006, 22:913-927.
22. Genest J., Frohlich J., Fodor G., et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003, 169:921-924.
23. Leiter L.A., Betteridge D.J., Chacra A.R., et al. Audit study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. Can J Diabetes Vasc Dis 2006, 6:31-40.
24. Leenen F.H., Dumais J., McInnis N.H., et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008, 178:1441-1449.
25. Chan J.C., Gagliardino J.J., Baik S.H., et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009, 32:227-233.
26. Santschi V., Chiolero A., Paradis G., et al. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care 2012, 35:2706-2717.
27. Watts S.A., Gee J., O'Day M.E., et al. Nurse practitioner-led multidisciplinary teams to improve chronic illness care: the unique strengths of nurse practitioners applied to shared medical appointments/group visits. J Am Acad Nurse Pract 2009, 21:167-172.
28. Campbell N.R., Poirier L., Tremblay G., et al. Canadian Hypertension Education Program: the science supporting new 2011 CHEP recommendations with an emphasis on health advocacy and knowledge translation. Can J Cardiol 2011, 27:407-414.